Echosens Announces Acceptance of Actuarial Study in American Journal of Managed Care: Positive Return on Investment of VCTE/CAP FibroScan Technology to Measure Liver Fat and Stiffness

WALTHAM, Mass.–(BUSINESS WIRE)–Echosens, a high-technology company offering the FibroScan family of products, announces acceptance of its article for publication of the findings of an independent assessment conducted by Santa Barbara Actuaries Inc. (SBA) to evaluate from the payer’s perspective the cost effectiveness of deploying VCTE / CAP machines (FibroScan®) for detecting and monitoring fatty liver disease (FLD). Scheduled for publication in 2021 by the American Journal of Managed Care, the report, “Population-Based Return on Investment of Deploying Transient Elastography Screening and Monitoring Fatty Liver Disease,” concluded that early identification of patients with FLD through broad placement of VCTE/CAP…